Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Healthcare industry will face higher medication errors, declining patient trust in 2022: Forrester

As the world enters the third year of the COVID-19 pandemic, the healthcare industry faces a variety of ongoing challenges and shifts in delivery of care, according to a new 2022 predictions report.

1. Health disparities will negatively impact rural Americans twice as much as urban Americans

2. Labor shortages will double the medication error rate among providers

3. Healthcare will no longer be considered a trusted industry as misinformation and cyberattacks continue

4. Sixty percent of virtual care visits will be related to mental health

5. The number of hospital-at-home providers will triple

Source: Fierce Healthcare

https://www.fiercehealthcare.com/digital-health/predictions-for-healthcare-2022

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!